Abstracts Archive - Page 1356 of 2607 - ACR Meeting Abstracts

Abstract Number: 2547 • 2018 ACR/ARHP Annual Meeting
Upadacitinib Monotherapy Improves Patient-Reported Outcomes in Patients with Rheumatoid Arthritis and Inadequate Response to Methotrexate
Vibeke Strand¹, Maya Buch², Namita Tundia³, Heidi S. Camp³, Jessica Suboticki³, Debbie Goldschmidt⁴ and Alvin F. Wells⁵, ¹Stanford University, Palo Alto, CA, ²NIHR Leeds Musculoskeletal Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ³AbbVie Inc., North Chicago, IL, ⁴Analysis Group Inc., New York, NY, ⁵Rheumatology and Immunotherapy Center, Franklin, WI
Background/Purpose: Upadacitinib (UPA) is a selective JAK-1 inhibitor with demonstrated patient-reported benefits in the treatment of active rheumatoid arthritis (RA).1,2 The objective of this analysis…
Abstract Number: 2548 • 2018 ACR/ARHP Annual Meeting
The Impact of Rheumatoid Arthritis on Patient-Reported Outcomes: Comparison between Sarilumab Clinical Trials and Real-World Patient Data
Vibeke Strand¹, Colleen M. Carpinella², Lulu K. Lee², Susan Boklage³ and Matthew Reaney⁴, ¹Stanford University School of Medicine, Palo Alto, CA, ²Kantar Health, San Mateo, CA, ³Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁴Sanofi, Guildford, United Kingdom
Background/Purpose: Rheumatoid arthritis (RA) and its treatment have significant impacts on health-related quality of life (HRQoL), work productivity (WP) and activity participation. Data are limited…
Abstract Number: 2549 • 2018 ACR/ARHP Annual Meeting
Patient-Reported Benefits of Sarilumab Monotherapy in Adult Patients with Active Rheumatoid Arthritis: Results from an Open-Label Extension Study
Vibeke Strand¹, Matthew Reaney², Erin Mangan³, Hubert van Hoogstraten⁴, Susan Boklage³ and Chih-Chi Hu⁵, ¹Stanford University School of Medicine, Palo Alto, CA, ²Sanofi, Guildford, United Kingdom, ³Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁴Sanofi Genzyme, Bridgewater, NJ, ⁵Sanofi, Bridgewater, NJ
Background/Purpose: Sarilumab is a human monoclonal antibody that binds to membrane and soluble IL-6R, which is approved for the treatment of moderate to severe rheumatoid…
Abstract Number: 2550 • 2018 ACR/ARHP Annual Meeting
Phase 3 Equira 48 Week Study Results Demonstrated No Impact on Efficacy and Safety When Patients with Moderate-to-Severe Rheumatoid Arthritis Were Switched between Reference Etanercept (ETN) and GP2015, an Etanercept Biosimilar
Arthur Kavanaugh¹, Marco Matucci-Cerinic², Hendrik Schulze-Koops³, Maya Buch⁴, Yannick Allanore⁵, Eugeniusz J. Kucharz⁶ and Goran Babic⁷, ¹UC San Diego School of Medicine, La Jolla, California, La Jolla, CA, ²Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy, ³Ludwig-Maximilians-University, Munich, Germany, Munich, Germany, ⁴University of Leeds, United Kingdom, Leeds, United Kingdom, ⁵Cochin Hospital, Paris Descartes University, Paris, France, Paris, France, ⁶Department of Internal Medicine and Rheumatology, Medical University of Silesia, Katowice, Poland, Katowice, Poland, ⁷Hexal AG, a Sandoz company, Holzkirchen, Germany, Holzkirchen, Germany
Background/Purpose: Compared to ETN, GP2015 has equivalent efficacy, and comparable safety and immunogenicity in patients with chronic plaque-type psoriasis.1 The purpose of this study is…
Abstract Number: 2551 • 2018 ACR/ARHP Annual Meeting
Rheumatoid Arthritis Treatment with Filgotinib: Week 132 Safety Data from a Phase 2b Open-Label Extension Study
Arthur Kavanaugh¹, Mark C. Genovese², Kevin Winthrop³, Maria Greenwald⁴, Lucia Ponce⁵, Favio Enriquez Sosa⁶, Mykola Stanislavchuk⁷, Minodora Mazur⁸, Alberto Spindler⁹, Regina Cseuz¹⁰, Natalya Nikulenkova¹¹, Maria Glowacka-Kulesz¹², Istvan Szombati¹³, Anna Dudek¹⁴, Neelufar Mozaffarian¹⁵, Joy Greer¹⁶, Rebecca Kunder¹⁵, Di An¹⁷, Luc Meuleners¹⁸, Robin Besuyen¹⁸, Rieke Alten¹⁹ and René Westhovens²⁰, ¹University of California, San Diego, School of Medicine, La Jolla, CA, ²Stanford University Medical Center, Palo Alto, CA, ³Oregon Health and Science University, Portland, OR, ⁴Desert Medical Advances, Palm Desert, CA, ⁵Cons. Priv. Temuco, Temuco, Chile, ⁶Clinstile SA de CV, Col., Mexico City, Mexico, ⁷Rheumatology, Vinnytsia Regional Clinical Hospital, Vinnytsia, Ukraine, ⁸IMSP Inst. de Cardiologie, Chisinau, Moldova, The Republic of, ⁹Centro Médico Privado de Reumatología, Centro Médico Privado de Reumatología, Argentina, ¹⁰Revita Reumatologiai Kft, Budapest, Hungary, ¹¹Vladimir Reg Clin Hosp, Vladimir, Russian Federation, ¹²Silesiana Centrum Medyczne, Wroclawska, Poland, ¹³Qualiclinic Kft., Budapest, Hungary, ¹⁴AMED Medical Center, Warsaw, Poland, ¹⁵Gilead Sciences, Inc., Foster City, CA, ¹⁶Gilead Sciences, Inc, Foster City, CA, ¹⁷Gilead Science, Inc., Foster City, CA, ¹⁸Galapagos NV, Mechelen, Belgium, Mechelen, Belgium, ¹⁹Schlosspark-Klinik University Medicine, Berlin, Germany, ²⁰Rheumatology, University Hospital KU Leuven, Leuven, Belgium
Background/Purpose: The orally administered, selective inhibitor of Janus Kinase 1 (JAK1), filgotinib (FIL), is currently being investigated for the treatment of rheumatoid arthritis (RA) in…
Abstract Number: 2552 • 2018 ACR/ARHP Annual Meeting
Fatigue in Psoriatic Arthritis Patients Treated with Intravenous Golimumab: Early Improvement Is Associated with Week 24 Outcomes in Acr 20, 50, and Health-Related Quality of Life
Arthur Kavanaugh¹, M. Elaine Husni², Eric K. H. Chan³, Diane D. Harrison⁴, Lilianne Kim⁴, Kim Hung Lo⁴, Elizabeth C Hsia⁵ and Chenglong Han⁶, ¹University of California, San Diego, School of Medicine, La Jolla, CA, ²Orthopedic and Rheumatologic Institute, Cleveland Clinic, Cleveland, OH, ³Janssen Global Services, LLC, Raritan, NJ, ⁴Janssen Research & Development, LLC, Spring House, PA, ⁵Janssen Research & Development, LLC/University of Pennsylvania, Spring House/Philadelphia, PA, ⁶Janssen Global Services, LLC, Malvern, PA
Background/Purpose: To investigate improvement in fatigue in adult patients with active psoriatic arthritis (PsA) treated with intravenously administered (IV) golimumab, an anti-TNFα…
Abstract Number: 2553 • 2018 ACR/ARHP Annual Meeting
Secukinumab Provides Early and Sustained Improvements in Health-Related Quality of Life in Patients with Psoriatic Arthritis: Pooled Results from the Secukinumab Phase 3 Trial Program
Vibeke Strand¹, Oliver FitzGerald², Laura C. Coates³, Jessica Walsh⁴, Juan D. Cañete⁵, Peter Nash⁶, Eric Davenport⁷, Luminita Pricop⁸, Gregory Hustache⁹, Nicolas Scheuer⁹, Isabelle Gilloteau⁹ and Matthias Augustin¹⁰, ¹Stanford University, Palo Alto, CA, USA, Palo Alto, CA, ²St Vincent's University Hospital and Conway Institute, University College Dublin, Ireland, Dublin, Ireland, ³University of Oxford, Oxford, UK, Oxford, United Kingdom, ⁴University of Utah School of Medicine, Salt Lake City, UT, USA, Salt Lake City, UT, ⁵Rheumatology Deparment, Hospital Clinic and IDIBAPS, Barcelona, Spain, Barcelona, Spain, ⁶University of Queensland, Brisbane, Queensland, Australia, St Lucia, Brisbane, Australia, ⁷RTI Health Solutions, Research Triangle Park, NC, USA, Research Triangle Park, NC, ⁸Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, East Hanover, NJ, ⁹Novartis Pharma AG, Basel, Switzerland, Basel, Switzerland, ¹⁰University Medical Center Hamburg-Eppendorf, Hamburg, Germany, Hamburg, Germany
Background/Purpose: Improving health-related quality of life (HRQoL) is a key goal of psoriatic arthritis (PsA) therapy. Secukinumab, a fully-human IL-17A inhibitor, has been shown to…
Abstract Number: 2554 • 2018 ACR/ARHP Annual Meeting
Abatacept without Methotrexate in Patients with Active Psoriatic Arthritis: A Post Hoc Analysis of a Phase III, Randomized Study
Vibeke Strand¹, Thomas Lehman², Harris A Ahmad², Alyssa Johnsen², Sandhya Balachandar² and Philip J. Mease³, ¹Stanford University, Palo Alto, CA, ²Bristol-Myers Squibb, Princeton, NJ, ³Swedish Medical Center and University of Washington School of Medicine, Seattle, WA
Background/Purpose: In the randomized, placebo (pbo)-controlled Phase III ASTRAEA study (ClinicalTrials.gov, NCT01860976) patients (pts) with active psoriatic arthritis (PsA) were randomized to abatacept (ABA) or…
Abstract Number: 2555 • 2018 ACR/ARHP Annual Meeting
Ixekizumab Treatment Results in Rapid and Sustained Improvements in the Disease Activity Index for Psoriatic Arthritis (DAPSA) in Patients Naïve to Biologic Dmards or with Previous Inadequate Response to TNF Inhibitors
Prashanth Sunkureddi¹, Baojin Zhu^2,3, Alexis Ogdie⁴, Aubrey Spraberry³, Jeffrey Lisse³, Chen-Yen Lin³ and David Shrom², ¹Rheumatology, Clear Lake Rheumatology Center, Nassau Bay, TX, ²LRL, Eli Lilly and Company, Indianapolis, IN, ³Eli Lilly and Company, Indianapolis, IN, ⁴University of Pennsylvania, Philadelphia, PA
Background/Purpose: The DAPSA is a composite tool that assesses several domains of psoriatic arthritis (PsA) manifestations and was developed as a disease activity measure for…
Abstract Number: 2556 • 2018 ACR/ARHP Annual Meeting
Secukinumab 150mg Provides Sustained Improvements in the Signs and Symptoms of Active Ankylosing Spondylitis with Consistent Safety Profile and High Retention Rate: 4-Year Results from a Phase III Trial
Helena Marzo-Ortega¹, Joachim Sieper², Alan J. Kivitz³, Ricardo Blanco⁴, Martin Cohen⁵, Evie Maria Delicha⁶, Susanne Rohrer⁶ and Hanno Richards⁶, ¹NIHR LBRC, LTHT and LIRMM, University of Leeds, Leeds, United Kingdom, ²University Clinic Benjamin Franklin, Berlin, Germany, ³Altoona Center for Clinical Research, Duncansville, PA, ⁴Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁵McGill University, Montreal, QC, Canada, ⁶Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Secukinumab, a fully human monoclonal IgG1 antibody that neutralizes IL-17A, has shown significant and sustained improvement in the signs and symptoms of active ankylosing…
Abstract Number: 2557 • 2018 ACR/ARHP Annual Meeting
Efficacy of Ustekinumab on Spondylitis-Associated Endpoints in TNF-Naïve Active Psoriatic Arthritis Patients with Physician-Reported Spondylitis
Philip Helliwell¹, Dafna D Gladman², Soumya D Chakravarty³, Shelly Kafka⁴, Chetan S Karyekar⁴, Yin You⁵, Arthur Kavanaugh⁶ and Lianne S. Gensler⁷, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, UK, Leeds, United Kingdom, ²Department of Medicine, Toronto Psoriatic Arthritis Research Program, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Janssen Scientific Affairs, LLC/Drexel University School of Medicine, Horsham/Phila, PA, ⁴Janssen Scientific Affairs, LLC, Horsham, PA, ⁵Janssen Research & Development, LLC, Spring House, PA, ⁶University of California, San Diego, School of Medicine, La Jolla, CA, ⁷University of California San Francisco, San Francisco, CA
Background/Purpose: In PSUMMIT 1&2, Phase 3 trials of ustekinumab (UST) in adults w/ active psoriatic arthritis (PsA), 30.1% & 22.4% of patients (pts) had peripheral…
Abstract Number: 2558 • 2018 ACR/ARHP Annual Meeting
Efficacy and Safety Outcomes in Patients with Axial Spondyloarthritis Treated with Certolizumab Pegol: Results from the 48-Week Run-in Part of a Withdrawal Study (NCT02505542)
Robert B.M. Landewé¹, Désirée van der Heijde², Maxime Dougados³, Xenofon Baraliakos⁴, Filip van Den Bosch⁵, Bengt Hoepken⁶, Karen Thomas⁶ and Lianne S. Gensler⁷, ¹Amsterdam Rheumatology & Clinical Immunology Center, Amsterdam and Zuyderland MC, Heerlen, Netherlands, ²Leiden University Medical Centre, Leiden, Netherlands, ³Rheumatology B Department, Paris-Descartes University and Cochin Hospital, Paris, France, ⁴Ruhr-University Bochum, Herne, Germany, ⁵Department of Internal Medicine, Ghent University Hospital, Ghent, Belgium, ⁶UCB Pharma, Monheim, Germany, ⁷University of California, San Francisco, CA
Background/Purpose: C-OPTIMISE is the first trial to evaluate whether certolizumab pegol (CZP) can be reduced/discontinued in patients with radiographic(r)-axSpA/ankylosing spondylitis (AS) and non-radiographic(nr)-axSpA achieving sustained…
Abstract Number: 2559 • 2018 ACR/ARHP Annual Meeting
Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis and Previous Inadequate Response to TNF Inhibitors: Two-Year Follow-up from a Phase 3 Study
Ana-Maria Orbai¹, Amanda M. Gellett², Lisa Kerr² and Arnaud Constantin³, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Eli Lilly and Company, Indianapolis, IN, ³Hopital Pierre-Paul Riquet, Toulouse, France
Background/Purpose: Ixekizumab (IXE), a high-affinity monoclonal antibody that selectively targets IL-17A, was superior to placebo (PBO) at Week (Wk) 24 for treating PsA signs and…
Abstract Number: 2560 • 2018 ACR/ARHP Annual Meeting
Efficacy of Guselkumab in Psoriasis Patients with Self-Reported Psoriatic Arthritis with Involvement of the Scalp, Nails, Hands, and Feet: A Pooled Analysis from 2 Pivotal Phase 3 Psoriasis Studies
Ana-Maria Orbai¹, Soumya D Chakravarty², Yin You³, Shelly Kafka⁴, Chetan S Karyekar⁴ and Joseph F. Merola⁵, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Janssen Scientific Affairs, LLC/Drexel U School of Medicine, Horsham/Phila, PA, ³Janssen Research & Development, LLC, Spring House, PA, ⁴Janssen Scientific Affairs, LLC, Horsham, PA, ⁵Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: VOYAGE 1 & 2 were the pivotal Ph3 GUS trials for plaque PsO.1,2 Here we compare efficacy of GUS vs PBO & adalimumab (ADA)…
Abstract Number: 2561 • 2018 ACR/ARHP Annual Meeting
Rapid and Sustained Improvements in Patient-Reported Signs and Symptoms with Ixekizumab in Biologic-Naive and TNF-Inadequate Responder Patients with Psoriatic Arthritis
Ana-Maria Orbai¹, Dafna D Gladman², Julie Birt³, Amanda M. Gellett³, Chen-Yen Lin³ and Tore Kvien⁴, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²University of Toronto, Toronto, ON, Canada, ³Eli Lilly and Company, Indianapolis, IN, ⁴Diakonhjemmet Hospital, Oslo, Norway
Background/Purpose: Ixekizumab (IXE), a high-affinity mAb that selectively targets IL-17A, has shown improvements up to Week (Wk) 24 across several domains of PsA (including ACR20)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].